Cytokinetics, Incorporated (CYTK)

Market Cap	8.89B +24.6%
Revenue (ttm)	67.67M -21.1%
Net Income	-894.00M
EPS	-7.18
Shares Out	139.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,665,140
Open	64.81
Previous Close	63.43
Day's Range	63.81 - 65.57
52-Week Range	54.30 - 88.31
Beta	0.41
Analysts	Buy
Price Target	109.40 (+71.15%)
Est. Earnings	Nov 4, 2026

About CYTK

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 673
• Stock Exchange: Nasdaq
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Analyst Summary

According to 22 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $109.4, which is an increase of 71.15% from the latest price.

Price Target

$109.4

(71.15% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error